40 results on '"Trumper, Lorenz"'
Search Results
2. Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
3. ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
4. ICGC-ARGO precision medicine: familial matters in pancreatic cancer
5. Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) as Frontline Treatment for Patients with CD30-Expressing PERIPHERAL T-Cell Lymphomas (Echelon-2): Impact of Consolidative Stem Cell Transplant
6. Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice
7. ICGC ARGO precision medicine: genomic profiling-informed prediction of immunotherapy response in two patients with metastatic head and neck squamous cell carcinoma
8. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).
9. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations
10. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
11. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma
12. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas
13. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
14. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
15. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma
16. Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma
17. ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
18. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
19. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
20. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
21. Immunoglobulin V Genes in Reed-Sternberg Cells
22. Immunoglobulin V Genes in Reed-Sternberg Cells
23. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination
24. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
25. ICGC-ARGO precision medicine: familial matters in pancreatic cancer
26. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
27. Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
28. Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)
29. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
30. Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results
31. Radioimmunotherapy efficiency and safety in consolidation and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An updated analysis of 230 patients of the international RIT-network.
32. A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia.
33. A Randomized Comparison of Total-Marrow Irradiation, Busulfan and Cyclophosphamide with Tandem High-Dose Melphalan in Patients with Multiple Myeloma.
34. Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.
35. MLL-Aberrations, Associated to T-AML, Are Induced by Chemotherapy In Vivo.
36. Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia
37. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomasThe authors dedicate this paper to Reza Parwaresch, who served as a reference pathologist for the German Low‐Grade Lymphoma Study Group (GLSG) over many years and who died unexpectedly in November 2005.: Results of a prospective randomized trial of the German Low‐Grade Lymphoma Study Group
38. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL)
39. Glucagonoma syndrome and bronchial carcinoma.
40. Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.